{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T15:31:24Z","timestamp":1793633484754,"version":"4.5.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020655","name":"European Health and Digital Executive Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.lanepe.2026.101868","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:21:15Z","timestamp":1790868075000},"page":"101868","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Biosimilar uptake policies in Europe: a cross-country mixed-methods policy analysis"],"prefix":"10.1016","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4853-4397","authenticated-orcid":false,"given":"Sabine","family":"Vogler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Habimana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Knoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u017cbieta","family":"Kuriata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Leoszkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kacper","family":"Mucha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Pelczarska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u017cbieta","family":"Skassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guenka","family":"Petrova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petya","family":"Milushewa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zornitsa","family":"Mitkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Tachkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Perelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrique","family":"Vasconcelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.lanepe.2026.101868_bib1","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S2213-2600(25)00163-8","article-title":"Arrival of biosimilars in respiratory medicine: towards improved access to biologics for patients","volume":"13","author":"van Boven","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"10464","key":"10.1016\/j.lanepe.2026.101868_bib2","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/S0140-6736(24)02151-2","article-title":"Driving down the cost of biologics: lessons from a nationalised health-care system","volume":"404","author":"Russell","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.lanepe.2026.101868_bib3","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S2468-1253(23)00003-1","article-title":"The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission","volume":"8","author":"Burisch","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101868_bib4","doi-asserted-by":"crossref","DOI":"10.1093\/jlb\/lsae020","article-title":"Biosimilar approval pathways: comparing the roles of five medicines regulators","volume":"11","author":"Knox","year":"2024","journal-title":"J Law Biosci"},{"issue":"9","key":"10.1016\/j.lanepe.2026.101868_bib5","article-title":"Biosimilars and the era of interchangeability","volume":"5","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.lanepe.2026.101868_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.healthpol.2023.104818","article-title":"Market diffusion of biosimilars in off-patent biologic drug markets across Europe","volume":"132","author":"B\u00f6hm","year":"2023","journal-title":"Health Policy"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101868_bib7","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s40259-024-00659-0","article-title":"Barriers and enablers affecting the uptake of biosimilar medicines viewed through the lens of actor network theory: a systematic review","volume":"38","author":"Rieger","year":"2024","journal-title":"BioDrugs"},{"key":"10.1016\/j.lanepe.2026.101868_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2024.1263472","article-title":"Policy measures and instruments used in European countries to increase biosimilar uptake: a systematic review","volume":"12","author":"Machado","year":"2024","journal-title":"Front Public Health"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101868_bib9","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s40259-025-00727-z","article-title":"Beyond cost: observations on clinical and patient benefits of biosimilars in real-world settings","volume":"39","author":"Kvien","year":"2025","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101868_bib10","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/S1470-2045(15)00381-2","article-title":"Postmarket policy considerations for biosimilar oncology drugs","volume":"17","author":"Renwick","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lanepe.2026.101868_bib11","doi-asserted-by":"crossref","first-page":"625296","DOI":"10.3389\/fphar.2021.625296","article-title":"Policies to encourage the use of biosimilars in European countries and their potential impact on pharmaceutical expenditure","volume":"12","author":"Vogler","year":"2021","journal-title":"Front Pharmacol"},{"issue":"12","key":"10.1016\/j.lanepe.2026.101868_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190147","article-title":"Policies for biosimilar uptake in Europe: an overview","volume":"12","author":"Moorkens","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.lanepe.2026.101868_bib13","series-title":"WHO Guideline on Country Pharmaceutical Pricing Policies","year":"2020"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101868_bib14","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s40259-025-00709-1","article-title":"Biosimilar policies and their impact on market penetration of adalimumab, etanercept and infliximab: a policy synthesis and descriptive analysis in 13 OECD countries","volume":"39","author":"Tam","year":"2025","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101868_bib15","doi-asserted-by":"crossref","DOI":"10.1080\/20523211.2026.2670697","article-title":"Pharmaceutical pricing and reimbursement information (PPRI): evolution and impact of a policy network over two decades","volume":"19","author":"Vogler","year":"2026","journal-title":"J Pharm Policy Pract"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101868_bib16","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1080\/14737167.2019.1667232","article-title":"Influence of biosimilar infliximab launch on the utilization pattern of biological medicines: the case of Hungary","volume":"20","author":"Harsanyi","year":"2020","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101868_bib17","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1080\/14737167.2019.1582334","article-title":"Price competition and reimbursement of biosimilar granulocyte-colony stimulating factor in Hungary","volume":"19","author":"Horny\u00e1k","year":"2019","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"10","key":"10.1016\/j.lanepe.2026.101868_bib18","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1111\/bcp.15859","article-title":"Effectiveness of biosimilar adoption within a UK tertiary hospital: 6-year follow-up","volume":"89","author":"Barron","year":"2023","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.lanepe.2026.101868_bib19","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3390\/ph13100324","article-title":"Learnings from regional market dynamics of originator and biosimilar infliximab and etanercept in Germany","volume":"13","author":"Moorkens","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.lanepe.2026.101868_bib20","first-page":"575","article-title":"Doctors commitment and long-term effectiveness for cost containment policies: lesson learned from biosimilar drugs","volume":"7","author":"Menditto","year":"2015","journal-title":"Clinicoecon Outcomes Res"},{"issue":"5","key":"10.1016\/j.lanepe.2026.101868_bib21","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s40258-023-00812-w","article-title":"What about offering a financial incentive directly to clinical units to encourage the use of biosimilars? Results of a two-year national experiment in France","volume":"21","author":"Tano","year":"2023","journal-title":"Appl Health Econ Health Policy"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101868_bib22","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s41669-024-00505-7","article-title":"Comparison of two financial incentives to encourage the use of adalimumab biosimilars: results of a French experiment close to clinicians","volume":"8","author":"Tano","year":"2024","journal-title":"PharmacoEcon Open"},{"key":"10.1016\/j.lanepe.2026.101868_bib23","series-title":"Biosimilar prescribing incentives: results of a French pilot of gainsharing between hospitals. Economie et Statistique\/Economics and Statistics","first-page":"147","author":"Attia","year":"2024"},{"issue":"5","key":"10.1016\/j.lanepe.2026.101868_bib24","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s11096-021-01243-0","article-title":"Uptake of biosimilars for TNF-\u03b1 inhibitors adalimumab and etanercept following the best-value biological medicine initiative in Ireland","volume":"43","author":"Duggan","year":"2021","journal-title":"Int J Clin Pharm"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101868_bib25","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1001\/jamainternmed.2020.0338","article-title":"Shift from adalimumab originator to biosimilars in Denmark","volume":"180","author":"Jensen","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101868_bib26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00228-019-02765-3","article-title":"The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars","volume":"76","author":"Jensen","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.lanepe.2026.101868_bib27","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s10389-025-02429-w","article-title":"Effects of the introduction of biosimilars on the costs and prescription frequency of selected biologics in statutory and private health insurance in Germany: differences and similarities","volume":"34","author":"Oppel","year":"2025","journal-title":"J Public Health"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101868_bib28","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12961-023-01015-4","article-title":"The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis","volume":"21","author":"Vandenplas","year":"2023","journal-title":"Health Res Policy Syst"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101868_bib29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.hlpt.2020.10.011","article-title":"Effective tools to manage biosimilars prescription: the Italian experience","volume":"10","author":"Guidotti","year":"2021","journal-title":"Health Policy Technol"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101868_bib30","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s40259-025-00721-5","article-title":"Demand- versus supply-side policies in market penetration of biosimilars: which is more effective?","volume":"39","author":"Shin","year":"2025","journal-title":"BioDrugs"},{"key":"10.1016\/j.lanepe.2026.101868_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.917814","article-title":"Switching among biosimilars: a review of clinical evidence","volume":"13","author":"Allocati","year":"2022","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101868_bib32","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/annrheumdis-2016-209166","article-title":"The changing landscape of biosimilars in rheumatology","volume":"75","author":"D\u00f6rner","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lanepe.2026.101868_bib33","series-title":"Study on best practices in the public procurement of medicines: Final report. Brussels: European Commission, European Health and Digital Executive Agency","author":"Vogler","year":"2022"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226002802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226002802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T15:17:14Z","timestamp":1793632634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776226002802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":33,"alternative-id":["S2666776226002802"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101868","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biosimilar uptake policies in Europe: a cross-country mixed-methods policy analysis","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101868","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101868"}}